Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Blood Advances|December 6, 2023
Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse populationJanine M Joseph, Jens Hillengass, Li Tang, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Kidney Medicine|August 5, 2024
Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 CasesWai Lun Will Pak, Natalie A Brumwell, Charlene C Kabel, et al.
The Journal of Experimental Medicine|May 6, 2009
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisDaniel Hirschhorn-Cymerman, Gabrielle A Rizzuto, Taha Merghoub, et al.
Blood|February 16, 2010
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organsTakeshi Nakahara, Hiroshi Uchi, Alexander M Lesokhin, et al.
Cancer Immunology Research|October 15, 2015
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyDavid J Chung, Katherine B Pronschinske, Justin A Shyer, et al.
Blood|June 26, 2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myelomaNikoletta Lendvai, Patrick Hilden, Sean Devlin, et al.
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
The Journal of Experimental Medicine|September 26, 2012
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeDaniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano, et al.
Leukemia & Lymphoma|July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion studyCesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
Pageof 9